Rapport Therapeutics appointment Jeffrey Sevigny as CMO

US clinical stage biotech Rapport Therapeutics (Nasdaq: RAPP) has announced the appointment of Dr Jeffrey Sevigny as chief medical officer (CMO), effective immediately.

A physician-scientist with more than 15 years of leadership in translational and clinical drug development, Dr.Sevigny has spearheaded ground-breaking research across neuroscience and rare diseases. His experience spans the full spectrum of development, from discovery to late-stage clinical trials and regulatory approvals, and with a strong record of portfolio development and building high-performing organizations, he brings deep strategic and operational experience to Rapport, the company said.

Dr Sevigny joins Rapport following his tenure as chief medical officer at Prevail Therapeutics, a wholly-owned subsidiary of Eli Lilly (NYSE: LLY), and senior vice president of neuroscience at Lilly. While at Prevail, Dr Sevigny built and led the company’s clinical development organization, while playing a pivotal role in the company’s corporate success, including rounds of financing, an initial public offering (IPO), and an acquisition by Lilly.